Fungal-derived compounds and mycogenic nanoparticles with antimycobacterial activity: a review

Abstract Tuberculosis (TB) is a persistent lung infection caused by Mycobacterium tuberculosis . The disease characterized high mortality rates of over 1 million per year. Unfortunately, the potency and effectiveness currently used anti-TB drugs gradually decreasing due to constant development persistence resistance M. adverse side effects associated with current drugs, along drug resistance, present an opportunity bio-prospect novel potent from unique sources. Fundamentally, fungi are rich source bioactive secondary metabolites valuable therapeutic potential. Enhancing fungal-based leads chemical synthesis and/or modification nanomaterials, may result in discovery drugs. In this review, antimycobacterial activity fungal-derived compounds mycogenic nanoparticles summarized. Numerous as well some that exhibit strong comparable approved were found. If fully explored, holds promise become key drivers generation lead TB-drug initiatives.